| Literature DB >> 35418766 |
Yongsheng Li1, Cheng Li2, Shi Zhao3, Yi Yin4, Xueliang Zhang5, Kai Wang5.
Abstract
Purpose: To establish an accurate risk prediction model of diabetic retinopathy (DR) using cost effective and easily available patients' characteristics and clinical biomarkers. Patients andEntities:
Keywords: diabetic peripheral neuropathy; nomogram; prediction model; risk factors
Year: 2022 PMID: 35418766 PMCID: PMC8999722 DOI: 10.2147/DMSO.S354611
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Figure 1Flow diagram of the data screening.
Clinical Characteristics of the Study Population (N=13,980)
| Variables | Without DR | With DR | P value | |
|---|---|---|---|---|
| n=8071 | n=5909 | |||
| DPN (%) | ||||
| No | 6768 (83.9%) | 1552 (26.3%) | <0.001a | |
| Yes | 1303 (16.1%) | 4357 (73.7%) | ||
| Gender (%) | ||||
| Male | 5366 (66.5%) | 3321 (56.2%) | <0.001a | |
| Female | 2705 (33.5%) | 2588 (43.8%) | ||
| Hypertension (%) | ||||
| No | 4253 (52.7%) | 2567 (43.4%) | <0.001a | |
| Yes | 3818 (47.3%) | 3342 (56.6%) | ||
| Age (%) | ||||
| ≤25 | 77 (1.0%) | 8 (0.1%) | <0.001a | |
| 25–40 | 951 (11.8%) | 180 (3.0%) | ||
| 40–55 | 3683 (45.6%) | 1902 (32.2%) | ||
| 55–70 | 2409 (29.8%) | 2650 (44.8%) | ||
| >70 | 951 (11.8%) | 1169 (19.8%) | ||
| WBC | 7.24±2.95 | 6.82±2.46 | <0.001b | |
| NE | 4.42±2.52 | 4.04±1.78 | <0.001b | |
| EOS | 0.16±0.24 | 0.17±0.15 | 0.862b | |
| LY | 2.20±0.81 | 2.17±0.85 | 0.016b | |
| Tc | 4.44±1.21 | 4.43±1.22 | 0.743b | |
| HDL | 1.01±0.32 | 1.10±0.33 | <0.001b | |
| LDL | 2.76±0.90 | 2.79±0.89 | 0.036b | |
| AST | 23.03±20.30 | 20.29±13.27 | <0.001b | |
| ALT | 29.61±29.26 | 24.02±22.29 | <0.001b | |
| Duration of T2DM (%) | ||||
| ≤5 | 5097 (63.2%) | 1359 (23.0%) | <0.001a | |
| 5–15 | 2369 (29.4%) | 2929 (49.6%) | ||
| 15–25 | 548 (6.8%) | 1440 (24.4%) | ||
| >25 | 57 (0.7%) | 181 (3.1%) | ||
| GLC | 9.47±5.12 | 10.21±5.33 | <0.001b | |
| HbA1C | 8.36±2.06 | 9.09±2.07 | <0.001b | |
| GSP | 2.79±0.80 | 2.97±0.80 | <0.001b | |
| ApoA1 | 1.17±0.26 | 1.22±0.25 | <0.001b | |
| ApoB | 0.94±0.29 | 0.93±0.29 | 0.12b | |
| TG | 2.49±2.51 | 2.18±2.08 | <0.001b | |
| Urea | 6.07±8.25 | 6.24±11.84 | 0.299b | |
Note: aRefers to chi square test, brefers to t-test.
Abbreviations: DPN, diabetic peripheral neuropathy; WBC, white blood cell; NE, neutrophilic granulocyte; EOS, eosinophil; LY, lymphocyte; Tc, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GLC, glucose; HbA1C, Hemoglobin A1c; GSP, glycosylated serum protein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; TG, triglyceride.
Figure 2Demographic and clinical feature selection using the LASSO binary logistic regression model (figure was created by R software, “glmnet” package, version 2.0–18, ).
Baseline Characteristics Were Analyzed by Multivariate Logistic Regression in the Training Group. (N= 10,485)
| OR (95% CI) | P value | |
|---|---|---|
| DPN | ||
| No | 1 | |
| Yes | 13.653 (12.261–15.220) | <0.001 |
| Age | 1.039 (1.034–1.044) | <0.001 |
| WBC | 1.043 (1.001–1.091) | 0.0574 |
| NE | 0.846 (0.801–0.891) | <0.001 |
| HDL | 1.856 (1.579–2.183) | <0.001 |
| HbA1C | 1.291 (1.252–1.331) | <0.001 |
| Duration of T2DM | 1.090 (1.081–1.100) | <0.001 |
| GSP | 1.120 (1.038–1.209) | 0.004 |
Abbreviations: DPN, diabetic peripheral neuropathy; WBC, white blood cell count; NE, neutrophilic granulocyte; HDL, high-density lipoprotein; HbA1C, Hemoglobin A1c; GSP, Glycosylated Serum Protein.
Figure 3Nomogram to predict the risk of DR.
Figure 4According to Nomogram’s estimate, the probability of DR risk in patient no.1020 (A) and no.2089 (B) was 0.12 and 0.816, respectively, P < 0.001.
Figure 5The ROC curves of the nomogram for DR risk (left, development group, right, validation group. including ROC curves of single risk factor model).
Figure 6Calibration curves for the validation and development group models (left, development group, right, validation group).
Figure 7The decision curve analysis of the nomogram for DR risk (left, development group, right, validation group).